---
title: "Goldman Sachs Sticks to Their Buy Rating for Carlsmed, Inc. (CARL)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282106154.md"
description: "Goldman Sachs analyst David Roman has reaffirmed a Buy rating for Carlsmed, Inc. (CARL) with a price target of $17.00. The analyst consensus for Carlsmed is a Strong Buy, with an average price target of $19.75. Roman specializes in the Healthcare sector and has an average return of -4.9% with a 37.65% success rate on his stock recommendations."
datetime: "2026-04-08T20:37:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282106154.md)
  - [en](https://longbridge.com/en/news/282106154.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282106154.md)
generator: "portal-rs"
---

# Goldman Sachs Sticks to Their Buy Rating for Carlsmed, Inc. (CARL)

Goldman Sachs analyst David Roman maintained a Buy rating on Carlsmed, Inc. today and set a price target of $17.00.

### Easter Sale - 70% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Roman covers the Healthcare sector, focusing on stocks such as Omada Health, Inc., Boston Scientific, and Insulet. According to TipRanks, Roman has an average return of -4.9% and a 37.65% success rate on recommended stocks. 

Currently, the analyst consensus on Carlsmed, Inc. is a Strong Buy with an average price target of $19.75.

### Related Stocks

- [CARL.US](https://longbridge.com/en/quote/CARL.US.md)

## Related News & Research

- [Carlsmed, Inc. (CARL) Gets a Buy from BTIG](https://longbridge.com/en/news/290616097.md)
- [Trump Is Still Very Much Operating Off ‘Concepts’ Of A Health Care Plan](https://longbridge.com/en/news/298872418.md)
- [Wedbush Keeps Their Buy Rating on Corbus Pharmaceuticals (CRBP)](https://longbridge.com/en/news/299048598.md)
- [Stifel Nicolaus Keeps Their Hold Rating on Sionna Therapeutics, Inc. (SION)](https://longbridge.com/en/news/299037622.md)
- [RBC Capital Keeps Their Hold Rating on Sanofi (SNYNF)](https://longbridge.com/en/news/298984745.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**